INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Fertility, Inc. (Nasdaq: IVF) on December 15, 2025. The filing discloses the entry into a Material Definitive Agreement to acquire the non-clinical assets of a fertility clinic in Indianapolis, Indiana, operated by Family Beginnings, P.C.
Key Financial Metrics and Transaction Terms
The transaction involves a combined purchase price of $750,000. The payment structure is as follows:
- Cash Consideration: $350,000 payable at closing, subject to a $150,000 holdback.
- Equity Consideration: $400,000 in Series D Non-Voting Convertible Preferred Stock.
- Closing Date: Expected no later than February 27, 2026.
- Price Adjustment: If closing occurs after January 31, 2026, the cash portion increases by $10,000.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company or the target clinic.
Material Changes and Transaction Structure
The Company is acquiring non-clinical assets only. Clinical assets, including patient lists, charts, records, payor contracts, and health care permits, are excluded from this purchase. Instead, a separate Florida professional association ("New PC") will acquire the clinical assets. The New PC will enter into a management services agreement to outsource non-medical activities to INVO and will employ the clinic's primary physician, Dr. James Donahue, for a minimum of three years. Dr. Donahue has agreed to a five-year non-compete and non-solicitation provision.
Outlook, Risks, and Contingencies
The transaction is contingent upon several conditions, including the execution of the separate clinical asset purchase agreement, the management services agreement, and the employment agreement with Dr. Donahue. The agreement includes a post-closing purchase price adjustment mechanism based on accounts receivable, supplies, debt, operating expenses, and prepaid amounts. If the closing does not occur by February 27, 2026, the agreement automatically terminates unless extended by mutual agreement.
Key Facts for Investor Verification
- Verify the final closing date to determine if the $10,000 cash price adjustment applies.
- Confirm the successful execution of the separate agreements regarding clinical assets and Dr. Donahue's employment, which are conditions precedent to the closing.
- Review the valuation and terms of the $400,000 Series D Non-Voting Convertible Preferred Stock issuance.
- Monitor the post-closing working capital adjustment calculation to determine the final cash settlement amount.